Skip to content

Mediterranean Diet and the Microbiota Gut Brain Axis in Major Depression

Mediterranean Diet and the Microbiota Gut Brain Axis- Does Diet Interact With the Function of Vagal Nerve in Major Depression?

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04772651
Acronym
MeDiVa
Enrollment
108
Registered
2021-02-26
Start date
2025-11-01
Completion date
2029-09-30
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

nutrition, mediterranean diet, vagal function, heart rate variability

Brief summary

The purpose of this study is to assess the efficacy of a Mediterranean diet on the function of the vagal nerve in patients with depression.

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will be screened for eligibility. Subjects meeting the inclusion criteria will be randomized in a group recieiving a Mediterranean diet (3 mediterranean meals a day) and dietary coaching (1 session per week for 4 weeks) or a group with conventional hospital food and psychoeducation on depression (1 session per week for 4 weeks).

Interventions

OTHERMediterranean Diet

Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)

OTHERNormal hospital diet

Normal hospital diet

OTHERdietary coaching

dietary coaching

OTHERPsychoeducation on depression

Psychoeducation on depression (50minutes once a week for 4 weeks)

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* legally competent persons aged 18-80 years * diagnosis of depression according to ICD-10 or DSM.

Exclusion criteria

* other neurologic or psychiatric disorders (epilepsy, brain tumor, head injury, head surgery, trauma) * drug or alcohol dependency * acute suicidality * heart disorders, disorders of the circulatory system * pregnancy and period of breastfeeding * severe mental disability, dementia (MMST\<20) * autoimmune disorder, severe immunosuppression (Lupus, HIV, multiple sclerosis) * therapy with antibiotics in the last month * chronic laxative abuse * acute infectious diarrhea * GI surgeries (except appendectomy) * regular intake of probiotics, antibiotics and food supplements (1 month before and during the study) * food allergies or other food intolerances which are incompatible with a mediterranean diet * vegetarians, vegans

Design outcomes

Primary

MeasureTime frameDescription
Change in Vagal functionat study entry, after 7 days, after 4 weeks and after 3 monthsVagal function measured by 24-hr ECG (logRSA, SDNN)

Secondary

MeasureTime frameDescription
Change in Interleukine-6at study entry, after 7 days, after 4 weeks and after 3 monthsInterleukine-6 will be measured from serum samples at the Institute of laboratory diagnostics
Change in Oxytocinat study entry, after 7 days, after 4 weeks and after 3 monthsmeasured from serum samples with ELISA
Change of Gut microbiomeat study entry, after 7 days, after 4 weeks and after 3 months16S sequencing of a stool sample, gut microbiome data will be analyzed with QIIME2 with regard to diversity metrices (alpha-diversity, beta-diversity) and differential bacterial abundance.
Change of Body mass Indexat study entry, after 7 days, after 4 weeks and after 3 monthsWeight will be measured with a calibrated scale, height will be measured with a non-expandable measuring tape. BMI will be calculated according to the formula \[kg/m2\].
Change in Hamilton Scale for Depression (HAMD)at study entry, after 7 days, after 4 weeks and after 3 monthsScale to rate severity of depressive symptoms; Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression
Change of C-reactive protein (CRP)at study entry, after 7 days, after 4 weeks and after 3 monthsCRP will be measured from serum samples at the Institute of laboratory diagnostics (Cobas analyzer)
Change in Pittsburgh Sleep Quality Inventory (PSQI)at study entry, after 7 days, after 4 weeks and after 3 monthsQuestionnaire to assess sleep quality; global PSQI score is calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.
Change in Adult Attachment Scaleat study entry, after 7 days, after 4 weeks and after 3 monthsQuestionnaire to assess attachment style in adults; The scale consists of 18 items scored on a 5 point likert-type scale. It measures adult attachment styles named Secure, Anxious and Avoidant, defined as: * Secure = high scores on Close and Depend subscales, low score on Anxiety subscale * Anxious = high score on Anxiety subscale, moderate scores on Close and Depend subscales * Avoidant = low scores on Close, Depend, and Anxiety subscales
Change in Wiener Ernährungsprotokollat study entry, after 7 days, after 4 weeks and after 3 months24-hr food recall
Change in Mediterranean Diet Scoreat study entry, after 7 days, after 4 weeks and after 3 monthsQuestionnaire rating the diet according to Mediterranean dietary style; three categories of adherence to the Mediterranean diet can be calculated (≤5, 6-9 and ≥10 points of the 14-item questionnaire)
Change in International Physical Acitivity Questionnaireat study entry, after 7 days, after 4 weeks and after 3 monthsQuestionnaire to rate physical activity; Physical activity is given in MET-minutes (METs are multiples of the resting metabolic rate)
Change in Beck Depression Inventory (BDI)at study entry, after 7 days, after 4 weeks and after 3 monthsSelf-rated scale to rate severity of depressive symptoms; Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depression.

Contacts

Primary ContactSabrina Mörkl, DDr.
sabrina.moerkl@medunigraz.at004331638581743
Backup ContactEva Reininghaus, Prof.
eva.reininghaus@medunigraz.at

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026